Clinical trial
Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With…
NCT00198393 · Intergroupe Francophone de Cancerologie Thoracique, Other · Completed
Key facts
| NCT number | NCT00198393 |
|---|---|
| Title | Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV |
| Official title | Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV |
| Lead sponsor | Intergroupe Francophone de Cancerologie Thoracique, Other |
| Collaborators | AstraZeneca Industry Sanofi |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Gefitinib, gemcitabine, Docetaxel |
| Enrollment | 126 |
| Start date | Nov 1, 2004 |
| Primary completion | Jun 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 30, 2010 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: